tesaglitazar (Galida)
Jump to navigation
Jump to search
Introduction
Glitazar in clinical trials
Indications
Dosage
* 0.5-3.0 mg PO QD * phase 3 clinical trials for 1.0 & 2.0 mg PO QD
Adverse effects
- may be more likely than thiazolidinediones to cause edema & heart failure * 60% discontinuation of drug at 3 mg QD
Mechanism of action
- glitazar, a so-called 2 in 1 drug
- improves blood glucose similar to thiazolidinediones
- improves lipid profile similar to fibrates
- lowers triglycerides up to 40% (3 mg QD)
- lowers LDL up to 17% (3 mg QD)
- activates both PPAR-alpha & PPAR-gamma
- activation of PPAR-gamma decreases plasma glucose & free fatty acid concentrations
- activation of PPAR-alpha receptors decreases plasma triglyceride & increases plasma HDL cholesterol
More general terms
References
- ↑ Prescriber's Letter 12(9): 2005 Diabetes Drugs on the Horizon: Investigational Drug: Muraglitazar (Pargluva) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210905&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Internal Medicine News 38(16) August 2005